Work

A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors

Year: 2010

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-009-9374-x

Authors: Howard A. Burris, Suzanne F. Jones, Daphne D. Williams, Steven J. Kathman, Jeffrey P. Hodge, Lini Pandite, Peter T. C. Ho, Scott A. Boerner, Patricia LoRusso

Institutions: Sarah Cannon Research Institute, Sarah Cannon, GlaxoSmithKline (United Kingdom), The Barbara Ann Karmanos Cancer Institute

Language: English

Topic: Microtubule and mitosis dynamics

Subfield: Cell Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1999184952

FWCI: 2.412

Cites: 22

Cited by: 59

Related to: 10